Omomyc is a 91-aminoacid protein derived from the MYC basic Helix-Loop-Helix leucine zipper (bHLHZ) domain that acts as a dominant negative molecule, inhibiting MYC/MYCN/L-MYC association with MAX, with positive therapeutic effects in cancer models. Omomyc has been developed into a therapeutic miniprotein for solid tumor treatment and recently reached clinical stage. OmoMYC lentivirus (TET-inducible, Puro) expresses OmoMYC control of the TRE3G promoter with puromycin as a selection marker. With PGK promoter driven Tet-On 3G, Omomyc expression can be induced by doxycycline .